Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 4Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Genitourinary 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 562Specimen Handling 490Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 406Radiotherapy 353Gemcitabine 314Bevacizumab 313Paclitaxel 298Biopsy 290Drug Therapy 283Blood Specimen Collection 248Capecitabine 245Oxaliplatin 241fludarabine 240Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 205Dexamethasone 187Radiosurgery 182Rituximab 159Standard of Care 158Pemetrexed 156Surgical Procedures, Operative 148durvalumab 145atezolizumab 145Leucovorin 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × 18-O-demethylcervinomycin A2 × Clear all
NCT05351788 2026-05-12

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Recruiting
110 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07296809 2026-05-08

SKB500 Combinations in Patients With Small Cell Lung Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Recruiting
80 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT07371208 2026-01-27

ST-A-TN

Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
40 enrolled
Breast

Breast Neoplasms

NCT07179783 2025-09-18

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Tianjin Medical University Second Hospital

Phase 2 Recruiting
28 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡